Novel psoriatic microenvironment score predicts treatment response

  • Wang G & al.
  • JAMA Dermatol
  • 02.09.2020

  • von Brian Richardson, PhD
  • Clinical Essentials
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • The novel psoriatic microenvironment (PME) score, based on expression values of 33 genes, is associated with clinical response in patients with psoriasis receiving systemic treatment.

Why this matters

  • The PME score predicts response to therapy before apparent clinical changes.

Key results

  • High PME score, characterized by keratinocyte differentiation, was associated with better treatment response (75.8% improvement in Psoriasis Area and Severity Index [PASI]; P=.03).
  • Low PME score, characterized by an immune activation signature, was associated with worse treatment response (53.5% improvement in PASI; P=.03).
  • PME score correlated with responder status up to 8 weeks earlier than PASI reduction in patients treated with etanercept, methotrexate plus adalimumab, or tofacitinib.

Study design

  • 1145 skin samples from 12 retrospective psoriasis studies were analyzed.
  • Funding: National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Limitations

  • Retrospective analysis. ­